Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-01-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
第四届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the ninth meeting of the fourth board of directors of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and the approval of several proposals including related party transactions, bank credit applications, guarantees for subsidiaries, and the scheduling of a shareholders' meeting. The document does not contain financial statements or detailed financial data but rather reports on board decisions and meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (1749 characters) and is a meeting resolution announcement, not a full report or financial disclosure. Therefore, the appropriate classification is MANG with high confidence.
2022-01-21 Chinese
独立董事关于第四届董事会第九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to the company's board meeting agenda, specifically about anticipated related-party transactions for the year 2022. It references compliance with company law, securities law, stock exchange listing rules, and internal governance rules. The content focuses on governance and board-level oversight rather than financial results, audit, or shareholder voting outcomes. It is not a full report, earnings release, or regulatory filing of financial data. The document is best classified under Board/Management Information (MANG) as it concerns board meeting matters and independent directors' opinions on governance issues.
2022-01-21 Chinese
独立董事关于第四届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the company's expected 2022 routine related party transactions. It references compliance with stock exchange listing rules and company bylaws, and it concludes with agreement to submit the matter to the 2022 first extraordinary shareholders meeting. The content focuses on governance and board-level approval of related party transactions, not on financial results, audit, or earnings. It is not a full report but a board/management related announcement. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, classification is MANG with high confidence.
2022-01-21 Chinese
关于召开2022年第一次临时股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2022 first extraordinary general meeting (临时股东大会) of shareholders for Xinxiang Tuoxin Pharmaceutical Co., Ltd. It includes information about the meeting date, time, location, agenda items, voting procedures (including online voting), registration details, and proxy forms. The content is focused on informing shareholders about the meeting and how to participate and vote on specific proposals. There are no financial statements, audit results, earnings data, or management discussion of financial results. The document is not a report but a formal meeting notice and related procedural information. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or for the Annual or Extraordinary General Meeting, including meeting notices and voting instructions.
2022-01-21 Chinese
关于公司及子公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's and its subsidiaries' application for a comprehensive credit line from banks. It includes details about the board meeting approving the proposal, the credit limit, and the purpose of the financing. There is no financial report, earnings data, or detailed financial statements. The document is a financing update related to capital structure and funding activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2022-01-21 Chinese
中天国富证券有限公司关于新乡拓新药业股份有限公司2022年度日常性关联交易预计的核查意见
Regulatory Filings
2022-01-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.